BDX

NYSE · Health Care

Becton Dickinson And Co

Q: Who are Becton Dickinson's main competitors?

Abbott Laboratories competes across diagnostics and medical devices in overlapping markets. Baxter International competes in infusion therapy and renal care. Medtronic and Stryker are formidable rivals in the interventional and surgical device segments. Cardinal Health and Owens & Minor compete on the distribution side. In diagnostics specifically, Roche, Siemens Healthineers, and bioMerieux are significant global competitors.

Q: Where is BDX trading today?

BDX last closed at $155.92, down 0.20% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $157.46 and a high of $235.34. The current price represents 0% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Q: What are analyst ratings for BDX stock?

Among 20 analysts covering BDX, the consensus rating is Hold — 9 rate it a buy, 11 hold, and 0 sell. The average price target sits at $211.74, implying 36% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Q: How much revenue does Becton Dickinson And Co generate?

Becton Dickinson And Co generated $21.62B in revenue during fiscal year 2026, with $1.66B reaching the bottom line as net income. The net profit margin of 7.7% reflects the competitive nature of its industry.

Q: What is the price-to-earnings ratio for BDX?

BDX trades at a P/E ratio of 29.60 on trailing earnings of $6.12 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

S&P 500 Large-Cap Stocks Blue Chip Stocks Healthcare Stocks Best Dividend Stocks

$155.92

-0.31 (-0.20%)

As of Mar 24, 9:33 PM ET ·

Day Range $154.09 — $157.05

52W Range $157.46 — $235.34

Performance

1D —

1W —

1M —

3M +1.02%

6M +7.44%

1Y -13.04%

YTD +1.74%

Open$154.67

Previous Close$156.23

Day High$157.05

Day Low$154.09

52W High$235.34

52W Low$157.46

Volume—

Avg Volume3.77M

Market Cap52.01B

P/E Ratio29.60

EPS$6.12

SectorHealth Care

Technical Indicators

Full analysis →

SMA 50 $160.79 Below

SMA 200 $148.04 Above

RSI (14) 78.3 Overbought

Trend Golden Cross Bullish

Analyst Ratings

Hold

20 analysts

9 Buy 11 Hold 0 Sell

Price Target +35.8% upside

Current
$155.92

Target
$211.74

$118.16 $211.74 avg $242.39

Key Financials

	FY 2026	FY 2025	FY 2024
Revenue	21.62B	20.59B	18.67B
Net Income	1.66B	1.42B	2.06B
Profit Margin	7.7%	7.3%	11.1%
EBITDA	4.92B	4.45B	4.26B
Free Cash Flow	—	—	1.84B
Rev Growth	+5.0%	+5.0%	-1.1%
Debt/Equity	0.76	0.76	0.42

Dividend

Dividend Yield2.30%

Annual Dividend$4.16

Payout Ratio71.3%

Frequencysemi-annual

Ex-DividendFeb 13, 2026

Pay DateFeb 23, 2026

About Becton Dickinson And Co

Becton, Dickinson and Company is a leading global medical technology company headquartered in Franklin Lakes, New Jersey, focused on improving medical discovery, diagnostics, and the delivery of care. The company manufactures and sells a broad portfolio of medical devices, instrument systems, and reagents across its three segments: BD Medical, BD Diagnostics, and BD Interventional. Its products include syringes, infusion therapy systems, diagnostic platforms, surgical instruments, and drug delivery solutions used by hospitals, laboratories, and clinicians worldwide. Becton, Dickinson is one of the largest medical technology companies in the world, competing with companies such as Abbott, Baxter, and Medtronic across multiple clinical specialties and geographic markets.

Health Care Peers

Symbol	Name	Price	Change	P/E	Mkt Cap
UNH	UnitedHealth Group Inc	$272.28	+1.02%	21.7	261.12B
ABT	Abbott Laboratories	$104.06	-0.75%	28.3	184.68B
ISRG	Intuitive Surgical Inc	$471.91	-1.28%	59.8	170.78B
SYK	Stryker Corp	$328.51	-1.23%	39.5	128.28B
MDT	Medtronic Plc	$86.58	-0.68%	24.1	111.30B
MCK	Mckesson Corp	$881.94	+0.56%	25.1	109.03B

BDX Frequently Asked Questions

What does Becton Dickinson do?

Becton Dickinson earns most of its revenue by making the workhorse products of modern medicine — syringes, needles, infusion systems, and diagnostic platforms that appear in almost every hospital and clinic worldwide. Its three segments address different parts of the care continuum: BD Medical focuses on medication management and drug delivery; BD Diagnostics supplies laboratory instruments and test reagents; and BD Interventional offers surgical and vascular devices. Scale and deep integration into hospital supply chains make switching difficult, while the recurring nature of single-use consumables drives predictable revenue streams.

Is BDX stock a good investment?

Becton Dickinson generates stable cash flows from its consumables-heavy business model, which provides resilience through economic cycles. Investors have long valued the company's consistent dividend growth, though the stock carries leverage from past acquisitions, particularly C.R. Bard. The company is working through a strategic portfolio review that may involve divestitures, which could improve free cash flow conversion and reduce debt. Revenue growth has been moderate, and execution on its innovation pipeline will likely determine whether the stock rerates higher.

Who are Becton Dickinson's main competitors?

Abbott Laboratories competes across diagnostics and medical devices in overlapping markets. Baxter International competes in infusion therapy and renal care. Medtronic and Stryker are formidable rivals in the interventional and surgical device segments. Cardinal Health and Owens & Minor compete on the distribution side. In diagnostics specifically, Roche, Siemens Healthineers, and bioMerieux are significant global competitors.

Does Becton Dickinson pay dividends?

Becton Dickinson has paid and increased its dividend for over 50 consecutive years, making it a Dividend King — one of a small group of companies with that distinction. The yield is modest relative to the overall healthcare sector, but the uninterrupted growth streak reflects a business model that consistently generates enough cash to reward shareholders while funding acquisitions and R&D. Management has treated the dividend as a non-negotiable commitment even during periods of elevated debt.

Where is BDX trading today?

BDX last closed at $155.92, down 0.20% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $157.46 and a high of $235.34. The current price represents 0% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

What are analyst ratings for BDX stock?

Among 20 analysts covering BDX, the consensus rating is Hold — 9 rate it a buy, 11 hold, and 0 sell. The average price target sits at $211.74, implying 36% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

How much revenue does Becton Dickinson And Co generate?

Becton Dickinson And Co generated $21.62B in revenue during fiscal year 2026, with $1.66B reaching the bottom line as net income. The net profit margin of 7.7% reflects the competitive nature of its industry.

What is the price-to-earnings ratio for BDX?

BDX trades at a P/E ratio of 29.60 on trailing earnings of $6.12 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

How has BDX performed compared to last year?

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +1.02% (3M), +7.44% (6M), -13.04% (1Y), +1.74% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether BDX is outperforming or lagging the broader market.